secwatch.observer — SEC 8-K summary
======================================

Issuer:     SYNLOGIC, INC. (SYBX)
CIK:        0001527599
Form:       8-K
Filed at:   2021-11-10T23:59:59+00:00
Accession:  0001193125-21-325370
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Synlogic reports Q3 net loss $16M; PKU Phase 2 shows proof of concept, moving to Phase 3
--------------------------------------------------------------------------------

- Interim Phase 2 SynPheny-1 data: SYNB1618 achieved proof of concept with statistically significant Phe reduction in PKU patients.
- SYNB1934 showed 2x improvement in Phe metabolism biomarkers vs SYNB1618; Phase 3 start planned in 2022.
- Cash, equivalents and short-term investments $150.1M as of Sept 30, 2021; net proceeds $48.4M from public offering.
- Revenue $0.9M from Roche IBD collaboration; first milestone payment earned; no further SYNB1891 studies planned.
- Net loss $16.0M ($0.29/share) vs $13.2M ($0.36/share) in Q3 2020; R&D expense $13.4M, G&A $3.6M.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521325370/0001193125-21-325370-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1527599/000119312521325370/d259422d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-325370

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer